J9351
J9351 – Injection, topotecan, 0.1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 8 NDCs crosswalked per 0.1 MG $2.759/unit ASP+6%
📋 J9351 summary
J9351 is a HCPCS Level II J-code used to bill topotecan, 0.1 mg, billed per 0.1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9351: Topotecan, Topotecan Hydrochloride, Hycamtin
Code J9351
Billing unit 0.1 MG Payment limit $2.759/unit NDC-Crosswalk 8
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9351
DescriptorInjection, topotecan, 0.1 mg
Billing unit0.1 MG
Payment limit / unit$2.759
Est. ASP / unit$2.603 est.
Mapped NDCs8
Data periodQ3 2026
Last updated2026-08-20
💊 About Topotecan Injection DRUG GUIDE
Topotecan injection is used to treat three types of cancer.
As a single agent, it treats metastatic ovarian cancer in patients whose disease has progressed during or after prior chemotherapy, and small cell lung cancer (SCLC) with platinum-sensitive disease that progressed at least 60 days after starting first-line chemotherapy.It is also used in combination with cisplatin to treat Stage IV-B, recurrent, or persistent cervical cancer that cannot be cured with standard treatments.
Clinical overview from our editorial drug guide for Topotecan Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.759
Est. ASP / unit
$2.603 est.
Est. after 2% sequester
$2.704
HCPCS dosage
0.1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, topotecan, 0.1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment group—
Action codeN — No maintenance this year
Effective date2018-01-01
Date added2011-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9351 = 0.1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9351 WITH EST. MEDICARE PAY
8 NDCs map to J9351. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.759/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00409-0302-01 | Topotecan 1 mg/mL INJECTION, SOLUTION, CONCENTRATE | Hospira, | 1 VIAL, SINGLE-DOSE in 1 CARTON (0409-0302... | 1 mg/mL | 40 | $110.36 | — | ● Active | CMS ASP |
| 16729-0151-31 | topotecan hydrochloride 4 mg/4mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Accord | 1 VIAL in 1 PACKAGE (16729-151-31) / 4 mL... | 4 mg/4mL | 40 | $110.36 | — | ● Active | CMS ASP |
| 16729-0243-31 | Topotecan 1 mg/mL INJECTION | Accord | 1 VIAL, MULTI-DOSE in 1 CARTON (16729-243-... | 1 mg/mL | 40 | $110.36 | — | ● Active | CMS + PDAC |
| 45963-0615-56 | Topotecan hydrochloride 4 mg/4mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Actavis | 1 VIAL in 1 CARTON (45963-615-56) / 4 mL... | 4 mg/4mL | 40 | $110.36 | — | ● Active | CMS + PDAC |
| 63323-0762-10 | Topotecan Hydrochloride 4 mg/4mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 1 VIAL in 1 BOX (63323-762-10) / 4 mL in... | 4 mg/4mL | 40 | $110.36 | — | ● Active | CMS ASP |
| 00078-0674-61 | HYCAMTIN topotecan hydrochloride 4 mg/4mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Novartis | 1 VIAL, SINGLE-DOSE in 1 CARTON (0078-0674... | 4 mg/4mL | 40 | $110.36 | — | ● Active | PDAC |
| 67457-0662-05 | TOPOTECAN (SDV) 1 MG/1 ML | Unknown | — | — | 10 | $27.59 | — | — | PDAC |
| 25021-0236-04 | TOPOTECAN HCL (1X4ML,PF) 1 MG/ML | Unknown | — | — | 10 | $27.59 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$32.4K
Claims
553
Beneficiaries
84
Spend / beneficiary
$386.14
Spend / claim
$58.65
Trend by period
Where J9351 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #629 of 824
#624
ALKERAN* J9245
$35.1K
#625
GANCICLOVIR SODIUM J1570
$34.8K
#626
BYOOVIZ Q5124
$34.5K
#627
DEPO-ESTRADIOL J1000
$33.6K
#628
SURGRAFT FT PER SQ C... Q4268
$33.2K
#629
TOPOTECAN HCL J9351
$32.4K
#630
GRANISETRON HCL J1626
$31.5K
#631
DUAL LAYER IMPAX, PE... Q4262
$31K
#632
CEFEPIME HCL J0692
$30.3K
#633
MODERNA COVID (6M-1... 91321
$30.1K
#634
MEROPENEM(J2185) J2185
$28.1K
Total claims — #444 of 824
#439
HALDOL DECANOATE 100... J1631
573
#440
PEMETREXED DISODIUM(... J9294
568
#441
DEXRAZOXANE J1190
567
#442
TESTOSTERONE ENANTHA... J3121
558
#443
DELESTROGEN* J1380
557
#444
TOPOTECAN HCL J9351
553
#445
CINQAIR J2786
540
#446
DACARBAZINE J9130
534
#447
BUMETANIDE J1939
532
#448
LYUMJEV J1813
526
#449
LEVOFLOXACIN-D5W J1956
524
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $32.4K | 84 | 553 | $386.14 | $58.65 |
| 2025 (Q1-Q4) | $237K | 282 | 2,930 | $840.56 | $80.90 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$241.4K
Medicare paid
$187K
Submitted services
145,905
Denial rate
3.7%
Allowed / service
$1.72
Submitted charges
$5.05M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J9351
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
8 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9351 billing FAQ
What is HCPCS code J9351?
J9351 is a HCPCS Level II J-code used to bill Injection, topotecan, 0.1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9351?
One unit of J9351 represents 0.1 MG. Report the number of units equal to the dose administered divided by 0.1 MG.
How many units of J9351 should I bill?
Divide the dose administered by the code's unit size (0.1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9351?
The Medicare Part B payment limit is $2.759 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.704 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9351?
8 NDCs currently map to J9351 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9351 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.